Apollomics (NASDAQ:APLM) Stock Price Breaks Below Two Hundred Day Moving Average – Here’s Why

Shares of Apollomics Inc. (NASDAQ:APLM) crossed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $19.01 and traded as low as $19.00. Apollomics shares last traded at $18.72, with a volume of 45,700 shares trading hands.

Analyst Ratings Changes

Several brokerages have recently commented on APLM. Wall Street Zen upgraded Apollomics to a “hold” rating in a report on Saturday, August 22nd. Weiss Ratings raised Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 17th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Apollomics Stock Performance

The stock’s 50-day moving average price is $23.00 and its 200-day moving average price is $19.01.

Insider Buying and Selling at Apollomics

In other news, COO Yi-Kuei Chen acquired 20,000 shares of the company’s stock in a transaction on Friday, August 14th. The stock was purchased at an average cost of $15.00 per share, with a total value of $300,000.00. Following the acquisition, the chief operating officer owned 121,248 shares of the company’s stock, valued at $1,818,720. This trade represents a 19.75% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Peter Lin bought 26,667 shares of the business’s stock in a transaction on Friday, August 14th. The shares were acquired at an average price of $15.00 per share, for a total transaction of $400,005.00. Following the completion of the transaction, the chief financial officer owned 48,979 shares in the company, valued at approximately $734,685. This trade represents a 119.52% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 583,334 shares of company stock worth $8,250,510.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Apollomics stock. Citadel Advisors LLC bought a new position in shares of Apollomics Inc. (NASDAQ:APLM) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 10,664 shares of the company’s stock, valued at approximately $224,000. Citadel Advisors LLC owned about 0.48% of Apollomics at the end of the most recent quarter. Hedge funds and other institutional investors own 19.13% of the company’s stock.

About Apollomics

Apollomics, Inc (NASDAQ:APLM) is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer. Its research programs are centered on immuno-oncology and precision oncology, with the goal of combining therapies that activate the immune system with treatments designed to target specific characteristics of tumors.

The company’s pipeline includes investigational small-molecule and antibody-based therapies intended for use across a range of solid tumors and blood cancers.